Hypoxia-inducible factor 1 in lower limb ischemia

Vascular

Volumn 14, Issue 6, 2006, Pages 321-327

  Ho, Teik K ^a   Abraham, David J ^a   Black, Carol M ^a   Baker, Daryll M ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Angiogenesis; Hypoxia inducible factor 1; Ischemia

Indexed keywords

ADENOVIRUS VECTOR; ANGIOGENIC FACTOR; CICLOPIROXOLAMINE; DEFEROXAMINE; DIBENZOYLMETHANE DERIVATIVE; DIMETHYLOXALYLGLYCINE; ENZYME INHIBITOR; HYDRALAZINE; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; IRON CHELATING AGENT; MITOGEN ACTIVATED PROTEIN KINASE; NAKED DNA; OXYGEN; PHOSPHATIDYLINOSITOL 3 KINASE; PROLYLHYDROXYLASE INHIBITOR; PROTEIN VP16; SOMATOMEDIN B; SOMATOMEDIN C; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ARTERY LIGATION; CELL DEATH; CELL PROLIFERATION; DRUG MECHANISM; FEMORAL ARTERY; GENE EXPRESSION; HUMAN; HYPOXIA; LEG ISCHEMIA; MUSCLE FUNCTION; MUSCLE ISCHEMIA; NEUROPROTECTION; NONHUMAN; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; VIRAL GENE THERAPY;

ANGIOGENIC PROTEINS; ANIMALS; CELL HYPOXIA; ENZYME INHIBITORS; GENE THERAPY; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; IRON CHELATING AGENTS; ISCHEMIA; LOWER EXTREMITY; MUSCLE, SKELETAL; NEOVASCULARIZATION, PHYSIOLOGIC; OXYGEN; PERIPHERAL VASCULAR DISEASES; PROCOLLAGEN-PROLINE DIOXYGENASE; TRANS-ACTIVATION (GENETICS);

EID: 34147200315     PISSN: 17085381     EISSN: None     Source Type: Journal    
DOI: 10.2310/6670.2006.00056     Document Type: Review

References (71)

1. Meijer WT, Hoes AW, Rutgers D, et al. Peripheral arterial disease in the elderly: The Rotterdam Study. Arterioscler Thromb Vasc Biol 1998;18:185-92.
2. Golledge J. Lower-limb arterial disease. Lancet 1997;350:1459-65.
3. Novo S, Coppola G, Milio G. Critical limb ischemia: definition and natural history. Curr Drug Targets Cardiovasc Haematol Disord 2004;4:219-25.
4. Risau W. Mechanisms of angiogenesis. Nature 1997;386:671-74.
5. Bashir R, Cooper CJ. Evaluation and medical treatment of peripheral arterial disease. Curr Opin Cardiol 2003;18:436-43.
6. Collinson DJ, Donnelly R. Therapeutic angiogenesis in peripheral arterial disease: can biotechnology produce an effective collateral circulation? Eur J Vasc Endovasc Surg 2004;28:9-23.
7. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000;6:389-95.
8. Cao R, Brakenhielm E, Pawliuk R, et al. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat Med 2003;9:604-13.
9. 2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev 1998;12:149-62.
10. Semenza GL, Agani F, Iyer N, et al. Regulation of cardiovascular development and physiology by hypoxia-inducible factor 1. Ann N Y Acad Sci 1999;874:262-8.
11. Semenza GL. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 2000;88:1474-80.
12. McClelland GB, Brooks GA. Changes in MCT 1, MCT 4, and LDH expression are tissue specific in rats after long-term hypobaric hypoxia. J Appl Physiol 2002;92:1573-84.
13. 2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 1999;15:551-78.
14. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001;294:1337-40.
15. 2 sensing. Science 2001;292:464-8.
16. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995;270:1230-7.
17. Wang GL, Semenza GL. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci U S A 1993;90:4304-8.
18. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A 1998;95:7987-92.
19. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003;9:677-84.
20. Jiang BH, Rue E, Wang GL, et al. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem 1996;271:17771-8.
21. Lee JW, Bae SH, Jeong JW, et al. Hypoxia-inducible factor (HIF-1)alpha: its protein stability and biological functions. Exp Mol Med 2004;36:1-12.
22. 2- regulated gene expression. FASEB J 2002;16:1151-62.
23. Minet E, Michel G, Mottet D, et al. Transduction pathways involved in hypoxia-inducible factor-1 phosphorylation and activation. Free Radic Biol Med 2001;31:847-55.
24. Semenza G. Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol 2002;64:993-8.
25. 2 sensing. J Biol Chem 2000;275:25130-8.
26. Zuo L, Clanton TL. Reactive oxygen formation in the transition to hypoxia in skeletal muscle. Am J Physiol Cell Physiol 2005;289: C207-16.
27. Rivard A, Berthou-Soulie L, et al. Age-dependent defect in vascular endothelial growth factor expression is associated with reduced hypoxia-inducible factor 1 activity. J Biol Chem 2000;275:29643-47.
28. Akakura N, Kobayashi M, Horiuchi I, et al. Constitutive expression of hypoxia-inducible factor-1alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res 2001;61:6548-54.
29. Bos R, Zhong H, Hanrahan CF, et al. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst 2001;93:309-14.
30. Talks KL, Turley H, Gatter KC, et al. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 2000;157:411-21.
31. Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999;59:5830-5.
32. Gayeski TE, Connett RJ, Honig CR. Oxygen transport in rest-work transition illustrates new functions for myoglobin. Am J Physiol 1985;248:H914-21.
33. 2 transport. J Clin Invest 1995;96:1916-26.
34. Richardson RS, Newcomer SC, Noyszewski EA. Skeletal muscle intracellular PO(2) assessed by myoglobin desaturation: response to graded exercise. J Appl Physiol 2001;91:2679-85.
35. Ameln H, Gustafsson T, Sundberg CJ, et al. Physiological activation of hypoxia inducible factor-1 in human skeletal muscle. FASEB J 2005;19:1009-11.
36. Yamakawa M, Liu LX, Date T, et al. Hypoxia-inducible factor-1 mediates activation of cultured vascular endothelial cells by inducing multiple angiogenic factors. Circ Res 2003;93: 664-73.
37. Vincent KA, Shyu KG, Luo Y, et al. Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1alpha/VP16 hybrid transcription factor. Circulation 2000; 102:2255-61.
38. Milkiewicz M, Pugh CW, Egginton S. Inhibition of endogenous HIF inactivation induces angiogenesis in ischaemic skeletal muscles of mice. J Physiol 2004;560:21-6.
39. Pajusola K, Kunnapuu J, Vuorikoski S, et al. Stabilized HIF-1alpha is superior to VEGF for angiogenesis in skeletal muscle via adeno-associated virus gene transfer. FASEB J 2005;19:1365-7.
40. Tuomisto TT, Rissanen TT, Vajanto I, et al. HIF-VEGF-VEGFR-2, TNF-alpha and IGF pathways are upregulated in critical human skeletal muscle ischemia as studied with DNA array. Atherosclerosis 2004;174:111-20.
41. Shavlakadze T, White J, Hoh JF, et al. Targeted expression of insulin-like growth factor-I reduces early myofiber necrosis in dystrophic mdx mice. Mol Ther 2004;10:829-43.
42. Ho TK, Rajkumar V, Ponticos M, et al. Increased endogenous angiogenic response and hypoxia-inducible factor-1alpha in human critical limb ischemia. J Vasc Surg 2006;43:125-33.
43. Yu EZ, Li YY, Liu XH, et al. Antiapoptotic action of hypoxia-inducible factor-1 alpha in human endothelial cells. Lab Invest 2004;84:553-61.
44. Shi Y. Mechanisms of caspase activation and inhibition during apoptosis. Mol Cell 2002;9:459-70.
45. Piret JP, Mottet D, Raes M, Michiels C. Is HIF-1alpha a pro- or an anti-apoptotic protein? Biochem Pharmacol 2002;64:889-92.
46. Ceradini DJ, Kulkarni AR, Callaghan MJ, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004;10:858-64.
47. Ceradini DJ, Gurtner GC. Homing to hypoxia: HIF-1 as a mediator of progenitor cell recruitment to injured tissue. Trends Cardiovasc Med 2005;15:57-63.
48. Urbich C, Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. Circ Res 2004;95:343-53.
49. Rehman J, Li J, Orschell CM, March KL. Peripheral blood "endothelial progenitor cells" are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation 2003; 107:1164-9.
50. Faucher M, Guillot C, Marqueste T, et al. Matched adaptations of electrophysiological, physiological, and histological properties of skeletal muscles in response to chronic hypoxia. Pflugers Arch 2005;450:45-52.
51. Chen EY, Mazure NM, Cooper JA, Giaccia AJ. Hypoxia activates a platelet-derived growth factor receptor/phosphatidylinositol 3-kinase/Akt pathway that results in glycogen synthase kinase-3 inactivation. Cancer Res 2001;61:2429-33.
52. Mazurek S, Boschek CB, Eigenbrodt E. The role of phosphometabolites in cell proliferation, energy metabolism, and tumor therapy. J Bioenerg Biomembr 1997;29:315-30.
53. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47.
54. Currin RT, Gores GJ, Thurman RG, Lemasters JJ. Protection by acidotic pH against anoxic cell killing in perfused rat liver: evidence for a pH paradox. FASEB J 1991;5:207-10.
55. Morimoto Y, Morimoto Y, Kemmotsu O, Alojado ES. Extracellular acidosis delays cell death against glucose-oxygen deprivation in neuroblastoma x glioma hybrid cells. Crit Care Med 1997;25:841-7.
56. Nielsen OB, de PF, Overgaard K. Protective effects of lactic acid on force production in rat skeletal muscle. J.Physiol 2001;536:161-6.
57. Mekhail K, Gunaratnam L, Bonicalzi ME, Lee S. HIF activation by pH-dependent nucleolar sequestration of VHL. Nat Cell Biol 2004; 6:642-7.
58. Mason SD, Howlett RA, Kim MJ, et al. Loss of skeletal muscle HIF-1alpha results in altered exercise endurance. PloS Biol 2004;2:e288.
59. Mack CA, Magovern CJ, Budenbender KT, et al. Salvage angiogenesis induced by adenovirus-mediated gene transfer of vascular endothelial growth factor protects against ischemic vascular occlusion. J Vasc Surg 1998;27:699-709.
60. Takeshita S, Tsurumi Y, Couffinahl T, et al. Gene transfer of naked DNA encoding for three isoforms of vascular endothelial growth factor stimulates collateral development in vivo. Lab Invest 1996; 75:487-501.
61. Tsurumi Y, Takeshita S, Chen D, et al. Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion. Circulation 1996;94:3281-90.
62. Simons M, Bonow RO, Chronos NA, et al. Clinical trials in coronary angiogenesis: issues, problems, consensus: an expert panel summary. Circulation 2000;102:E73-86.
63. Ivan M, Haberberger T, Gervasi DC, et al. Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc Natl Acad Sci U S A 2002;99:13459-64.
64. 2-regulated prolyl hydroxylation. Science 2001;292:468-72.
65. Warnecke C, Griethe W, Weidemann A, et al. Activation of the hypoxia-inducible factor-pathway and stimulation of angiogenesis by application of prolyl hydroxylase inhibitors. FASEB J 2003;17: 1186-8.
66. Knowles HJ, Tian YM, Mole DR, Harris AL. Novel mechanism of action for hydralazine: induction of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by inhibition of prolyl hydroxylases. Circ Res 2004;95:162-9.
67. Roy A, Volgin DV, Baby SM, et al. Activation of HIF-1alpha mRNA by hypoxia and iron chelator in isolated rat carotid body. Neurosci Lett 2004;363:229-32.
68. Hamrick SE, McQuillen PS, Jiang X, et al. A role for hypoxia-inducible factor-1alpha in desferoxamine neuroprotection. Neurosci Lett 2005;379:96-100.
69. Mabjeesh NJ, Willard MT, Harris WB, et al. Dibenzoylmethane, a natural dietary compound, induces HIF-1 alpha and increases expression of VEGF. Biochem Biophys Res Commun 2003;303: 279-86.
70. Elson DA, Thurston G, Huang LE, et al. Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1alpha. Genes Dev 2001;15:2520-32.
71. Paul SA, Simons JW, Mabjeesh NJ. HIF at the crossroads between ischemia and carcinogenesis. J Cell Physiol 2004;200:20-30.